4-溴吲哚-1-羧酸叔丁酯 | 676448-17-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 吲哚类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 4-溴吲哚-1-羧酸叔丁酯
• 中文别名: 1-BOC-4-溴吲哚；4-溴吲哚-1-羧基酸叔-丁基酯；N-BOC-4-溴-吲哚；4-溴吲哚-1-羧基 酸 叔-丁基 酯
• 英文名称: tert-butyl 4-bromo-1H-indole-1-carboxylate
• 英文别名: N-boc-4-bromoindole；1-Boc-4-Bromoindole；tert-butyl 4-bromoindole-1-carboxylate
• CAS: 676448-17-2
• 化学式: C₁₃H₁₄BrNO₂
• 分子量: 296.164
• InChiKey: ZGBNKNOAADXGOH-UHFFFAOYSA-N

物化性质

• 熔点：
  183 - 185°C
• 沸点：
  367.9±34.0 °C(Predicted)
• 密度：
  1.37±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（轻微、加热、超声处理）

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  31.2
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-BOC-4-Bromoindole
Synonyms: tert-butyl 4-bromo-1H-indole-1-carboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-BOC-4-Bromoindole
CAS number: 676448-17-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H14BrNO2
Molecular weight: 296.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-溴吲哚-1-羧酸叔丁酯 在 tris-(dibenzylideneacetone)dipalladium(0) 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 1-叔丁基-2,2,4,4,4-五(二甲氨基)-2Λ5,4Λ5-连二(磷氮基化合物) 、 三氟乙酸 、 sodium t-butanolate 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 11.0h， 生成 1-(苯基磺酰基)-4-(1-哌嗪)-1H-吲哚
  参考文献：
  名称：

  A dual-acting 5-HT6 receptor inverse agonist/MAO-B inhibitor displays glioprotective and pro-cognitive properties

  摘要：

  The complex etiology of Alzheimer's disease has initiated a quest for multi-target ligands to address the multifactorial causes of this neurodegenerative disorder. In this context, we designed dual-acting 5-HT6 receptor (5-HT6R) antagonists/MAO-B inhibitors using pharmacophore hybridization strategy. Our approach involved linking priviliged scaffolds of 5-HT6R with aryloxy fragments derived from reversible and irreversible MAO-B inhibitors. The study identified compound 48 that acts as an inverse agonist of 5-HT6R at Gs signaling and an irreversible MAO-B inhibitor. Compound 48 showed moderate metabolic stability in rat microsomal assay, artificial membrane permeability, no hepatotoxicity, and it was well distributed to the brain. Additionally, 48 showed glioprotective properties in a model of cultured astrocytes using 6-OHDA as the cytotoxic agent. Finally, compound 48 (MED = 1 mg/kg, p.o.) fully reversed memory deficits in the NOR task induced by scopolamine in rats. A better understanding of effects exerted by dual-acting 5-HT6R/MAO-B modulators may impact the future development of neurodegenerative-directed treatment strategies.

  DOI：

  10.1016/j.ejmech.2020.112765
• 作为产物：
  描述：

  tert-butyl 4-(((trifluoromethyl)sulfonyl)oxy)-1H-indole-1-carboxylate 在 tris-(dibenzylideneacetone)dipalladium(0) 、 2-二叔丁基膦-2′,4′,6′-三异丙基-3,6-二甲氧基-1,1′-联苯 、 三异丁基铝 、 丁酮 、 potassium bromide 作用下， 以 甲苯 为溶剂， 反应 24.0h， 以75%的产率得到4-溴吲哚-1-羧酸叔丁酯
  参考文献：
  名称：

  钯催化芳基和乙烯基三氟甲磺酸酯转化为溴化物和氯化物

  摘要：

  使用二烷基联芳基膦配体开发了钯催化的芳基和乙烯基三氟甲磺酸酯转化为芳基和乙烯基卤化物（溴化物和氯化物）。通过该方法可以以良好至优异的产率制备各种芳基、杂芳基和乙烯基卤化物。

  DOI：

  10.1021/ja107481a

文献信息

• Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
  申请人：AbbVie S.à.r.l.

  公开号：US20190077784A1

  公开（公告）日：2019-03-14

  The invention discloses compounds of Formula (I), wherein A 1 , R 1 , R 2 , R 3 , R 4 , and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

  该发明揭示了式（I）的化合物， 其中A 1 ，R 1 ，R 2 ，R 3 ，R 4 和n如本文所定义。本发明涉及化合物及其在囊性纤维化治疗中的应用，其生产方法，包含相同化合物的药物组合物，以及通过给予该发明的化合物来治疗囊性纤维化的方法。
• Rhodium( <scp>II</scp> )‐Catalyzed [4+3] Cyclization of Triazoles with Indole Derivatives and Its Application in the Total Synthesis of (±)‐Aurantioclavine
  作者：Shengguo Duan、Bing Xue、Hui Meng、Zihang Ye、Ze‐Feng Xu、Chuan‐Ying Li

  DOI：10.1002/cjoc.202000657

  日期：2021.5

  rhodium(II)‐catalyzed [4+3] cyclization reaction of 1‐sulfonyl‐1,2‐3‐triazoles and indoles was developed. Azepino[5,4,3‐ cd]indoles, which are widely distributed in ergot alkaloids with various biological activities, could be obtained in good to excellent yields. In addition, the total synthesis of (±)‐aurantioclavine was completed in four steps from the known compound 1a adopting this [4+3] cyclization as a key step

  开发了有效的铑（II）催化的1-磺酰基-1,2-3-3三唑和吲哚的[4 + 3]环化反应。可以以良好或极好的收率获得阿斯皮诺[5,4,3- cd ]吲哚，广泛分布在具有各种生物活性的麦角生物碱中。此外，采用这种[4 + 3]环化作为关键步骤，从已知化合物1a的四个步骤中完成了（±）-金葡糖醇的总合成。
• Fe-Catalyzed Reductive Couplings of Terminal (Hetero)Aryl Alkenes and Alkyl Halides under Aqueous Micellar Conditions
  作者：Haobo Pang、Ye Wang、Fabrice Gallou、Bruce H. Lipshutz

  DOI：10.1021/jacs.9b04510

  日期：2019.10.30

  aromatic or heteroaromatic and an alkyl bromide or iodide leads, in the presence of Zn and a catalytic amount of an Fe(II) salt, to a net reductive coupling. The new C-C bond is regiospecifically formed at rt at the -site of the al-kene. The coupling only occurs in an aqueous micellar medium, where an atypical carbanionic, as opposed to radical, process is likely, supported by several control experiments

  在Zn和催化量的Fe(II)盐的存在下，乙烯基取代的芳族或杂芳族和烷基溴或碘的组合导致净还原偶联。新的 CC 键在 rt 在烯烃的  位点区域特异性地形成。偶联仅发生在水性胶束介质中，其中可能是非典型的碳负离子过程，而不是自由基过程，这得到了几个控制实验的支持。提出了一种基于这些数据的机制。
• TREATMENT OF CANCERS HAVING K-RAS MUTATIONS
  申请人：Curis, Inc.

  公开号：US20130102595A1

  公开（公告）日：2013-04-25

  The present invention provides a method of treating a cancer associated with a K-ras mutation in a subject in need thereof. The method comprises the steps of: (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) administering to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

  本发明提供了一种治疗与K-ras突变相关的癌症的方法，适用于需要该方法的受试者。该方法包括以下步骤：（1）识别患有与K-ras突变相关的癌症的受试者；和（2）向受试者施用（i）PI3激酶抑制剂和（ii）HDAC抑制剂，其中PI3激酶抑制剂和HDAC抑制剂以联合治疗有效的剂量进行施用。
• [EN] TREATMENT OF CANCERS HAVING K-RAS MUTATIONS<br/>[FR] TRAITEMENT DE CANCERS PRÉSENTANT DES MUTATIONS K-RAS
  申请人：CURIS INC

  公开号：WO2011130628A1

  公开（公告）日：2011-10-20

  The present invention provides a method of treating a cancer associated with a K- ras mutation in a subject in need thereof. The method comprises the steps of (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) adminsiterign to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

  本发明提供了一种治疗与K-ras突变相关的癌症的方法，适用于需要该方法的受试者。该方法包括以下步骤：(1) 鉴定患有与K-ras突变相关的癌症的受试者；和 (2) 给予该受试者 (i) PI3激酶抑制剂和 (ii) HDAC抑制剂，其中PI3激酶抑制剂和HDAC抑制剂以治疗有效的剂量一起给予。